Research Nester recently published a report titled “Global Regenerative Medicines Market: Outlook, Industry Analysis & Opportunity Evaluation – 2018-2025” that delivers detailed overview of the global Regenerative Medicines market in terms of market segmentation by technology, source, applications, end-users and by regions.
Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, trends and regulations & policies.
The Regenerative Medicines market serves patients who suffer from various oncogenic, non-oncogenic, and immunologic to infectious and cardiovascular diseases. Application of regenerative medicines in tissue-engineering cartilages, modifying chondrocytes, and other tissue engineering technologies for treating traumatic and degenerative joint diseases is estimated to drive the market growth in the upcoming years. Additionally, increasing use of regenerative medicines in hepatocyte transplants for chronic liver disease treatments and liver failure conditions is propelling an exponential growth in the global market. Moreover, increasing use of poly-hemoglobin blood substitute produced through regenerative medicines to treat conditions of blood contamination or blood shortages is further propelling growth in the utilization of regenerative medicines in the hospitals, blood banks and research institutes.
Emerging economies such as India and China are presently experiencing extremely high demand for regenerative medicines especially gene therapy, tissue engineering, and cellular immune-therapy. Presence of high levels of physical and chemical carcinogens in the environment and presence of high smoking population across Japan, Australia, Singapore and South Korea are leading to increasing incidences of cancer. Increasing application of regenerative medicines in oncogenic disease treatments is projected to boost the market across Asia-Pacific.
On account of increase in cardiovascular disease patients on the back of increasing risk factors such as hypertension, diabetes, hyperlipidaemia is driving global regenerative medicine market across the globe. According to World Health Organization, around 17.9 million people died from CVDs in 2016 of 31% of all global deaths. Of these deaths, 85% are due to heart attack and strokes and over three quarters of CVD deaths take place in low and middle income countries which is projected to propel the growth of global regenerative medicine market over the forecast period.
A sharp reduction in the size of secondary care institutions across Europe in the past decade has resulted in the streamlining of healthcare delivery and stimulated more efficient and integrated model of care that is anticipated to lead to complete conquer of the hospital-centric pattern of care over the forthcoming years. These change in patterns of healthcare are attributed to influence the regenerative medicines market positively across Europe. Regionally, the market in Europe is projected to witness steep market growth and reach USD 64.32 Billion in terms of revenue by the end of 2027, while growing at a CAGR of 19.33% over the forecast period. Additionally, with the advent of a tie-up of financial and organizational measures lately, directed to improve integration and coordination between the different levels of care and more efficient methodologies of hospital financing in order to incentivize, appropriateness have been introduced that have resulted in increased use of day-hospital and day-surgery by replacement of daily payments known to have encouraged longer hospitalization. These constructive initiatives in the healthcare sector across the European region is propelling the growth of regenerative medicines market rapidly.
However, the growth of Regenerative Medicines market despite having exceptional qualities of providing competent is likely to suffer from some disadvantages. Stringent government regulations is estimated to play as a major factor in limiting the growth of global regenerative medicine market over the forecast period. There are extensive reimbursement challenges for regenerative medicine on the immediate horizon for biotechnology and pharmaceutical companies across the world. Additionally, AMPs (Accelerated Manufacture of Pharmaceuticals programs) are operating in Indonesia, Singapore, China, and Japan where cell products including vaccines are being mass produced. However, not a single AMP is used in the United States because of outdated government regulations which is expected to slow down the global regenerative medicines market growth.
This report also provides the existing competitive scenario of some of the key players of the Regenerative Medicines market which includes company profiling of Smith & Nephew Plc., Sangamo, Integra LifeSciences Corporation, Novartis, Stryker Corporation and other prominent players. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global Regenerative Medicines market that will help industry consultants, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.